469. ACS Guidelines Question #7 with Dr. Venu Menon

Managing cardiogenic shock in the setting of ST-elevation myocardial infarction (STEMI) requires careful selection of mechanical circulatory support (MCS) based on the 2025 ACS guidelines. For a 72-year-old patient with refractory shock and elevated filling pressures despite revascularization and vasopressors, the placement of a microaxial intravascular flow pump is the preferred intervention. This recommendation is supported by the DANGER shock trial, which demonstrated a 26% reduction in all-cause mortality and a 12.7% absolute risk reduction, though it carries increased risks of bleeding and renal replacement therapy. Dr. Venu Menon, a guideline writing committee member, explains that while the device received a Class IIa recommendation due to its mortality benefit, it fell short of Class I status because the trial excluded comatose and cardiac arrest patients, utilized a highly selective population over a ten-year period, and showed significant complication rates. Conversely, intra-aortic balloon pumps and VA ECMO are currently Class III recommendations for lack of benefit in this specific clinical context.